A simplified model of a human antibody made of Lego bricks has been built at the lobby at the headquarters of Seattle Genetics. The design signifies what Seattle Genetics, under Clay Siegall founder and CEO, has been studying, manipulating and packaging into drugs since its founding in 1998. The company’s antibodies have the power to connect with therapy and deliver a toxic payload into a cancer cell. That way, it destroys the cell from the inside. The strategy is expected to transform Seattle Genetics and catapult it to the big leagues. Seattle Genetics is among the largest biotech companies in Washington and is valued at $10 billion with a work force of 900 employees. The company hopes to add 200 more employees this year as it seeks to grow through research and marketing.
Seattle Genetics produces a drug called Adcetris, which is used in the treatment of Hodgkin lymphoma, a cancer of the lymph system. According to Clay Siegall, Seattle Genetics is an emerging global and multi-product Oncology Company that he seeks to build and grow to a great company, unlike many other rival bio tech companies that sell to larger companies. The company managed sales of about $418 million in 2016, up 46 percent from 2014. The stock price has also tripled in the last five years from $20 a share to $66 as of mid-May. Its drug Adcetris has been approved by the Food and Drug Administration (FDA) to be used by patients suffering from Hodgkin lymphoma as a second or third drug.
About Clay Siegall
Clay Siegall is the co-founder of Seattle Genetics and currently serves as the company’s President, CEO, and Chairman. He previously worked at the Bristol-Myers Squibb Pharmaceutical Research Institute. From 1988 to 1991, Siegall worked for the National Cancer Institute and the National Institutes of Health. He also serves as the director of Alder BioPharmaceuticals, Inc. and Mirna Therapeutics, Inc., which are private biotech companies. Clay Siegall graduated from the University of Maryland where he attained a B.S. in Zoology. He later attained a Ph.D. in Genetics from George Washington University. Clay Siegall has expertise and experience in the drug production industry.